Contract Pharma

CONTRACT PHARMA stands out as the sole global publication dedicated to Bio/Pharma contract services, boasting a verified circulation of 20,026. This publication offers more in-depth editorial content on contract services and outsourcing than any other source. In 2013 alone, we featured over 700 pages of editorial content centered on outsourcing across our nine issues. CONTRACT PHARMA holds the top position in advertising market share for contract services and outsourcing providers within the Pharma and Biopharma sectors.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#582903

United States

#335607

Health/Biotechnology and Pharmaceuticals

#321

Traffic sources

Monthly visitors

Articles

An Inflection Point in Obesity R&D

3 weeks ago | contractpharma.com | Kristin Brooks

The World Obesity Federation’s Global Obesity Observatory estimates that 1 billion adults will have obesity by 2030, and more than half of the world’s population1 will live with overweight or obesity levels by 2035. As such, there has been tremendous focus and growth in obesity drug development, with Wegovy (semaglutide) and Zepbound (tirzepatide) becoming household names in recent years.
From the Lab to Production

3 weeks ago | contractpharma.com | Tim Wright

Welcome to the April issue of Contract Pharma. This month’s edition highlights critical trends and challenges shaping the pharma manufacturing and development landscape, highlighting new regulatory requirements, advances in therapies, and shifts in manufacturing strategies. First, the pharmaceutical industry’s reliance on analytical testing has grown substantially, driven by increasing regulatory demands and the need for improved quality assurance.
Streamlining Compliance and Efficiency in Life Sciences: The Role of Wearables and Biometrics

3 weeks ago | contractpharma.com | Tim Wright

The life sciences industry operates under immense pressure to maintain product quality, meet strict regulatory standards and optimize efficiency. At the same time, many manufacturers struggle with outdated systems and processes that exacerbate bottlenecks, slow down production and increase the risk of noncompliance.
Overcoming Challenges in Early Phase Drug Product Development

3 weeks ago | contractpharma.com | Tim Wright

Formulation optimization during the scale-up process from preclinical through early phase clinical trials is crucial for maintaining control over dissolution rates, which directly impact the bioavailability and therapeutic efficacy of drug products. As drug candidates transition from the research lab to larger-scale production, managing factors such as particle size and formulation composition becomes essential to uphold the integrity and performance of the drug.
Losing Weight at the Touch of a Button

3 weeks ago | contractpharma.com | Tim Wright

Obesity and type 2 diabetes are not only widespread, they are also partly interrelated. People suffering from obesity have an increased risk of developing type 2 diabetes. According to estimates by the International Diabetes Federation, 540 million people worldwide are currently living with diabetes, more than 90 percent of whom have type 2.
Are you ready? FDA’s Nitrosamine Testing Deadline is August 1

3 weeks ago | contractpharma.com | Tim Wright

Testing for the presence of nitrosamines on pharmaceutical drug products will be a requirement on all prescription drugs, over-the-counter (OTC) drugs, and drug products in clinical development starting on August 1, 2025. This mandate ensures compliance with regulations from the U.S. Food and Drug Administration (FDA) as well as other global regulatory agencies.1,2 At the time of publication, organizations have less than four months remaining to comply with the new regulations.
The Rise of Aseptic Small-Batch Manufacturing

3 weeks ago | contractpharma.com | Tim Wright

What happens when a life-saving drug is delayed not because of science, but because the industry can’t keep up? That’s the crisis facing aseptic small-batch manufacturing today. Precision medicine, biologics, and orphan drugs are pushing the limits of conventional production. But most manufacturing processes weren’t designed for this. To survive, manufacturers must evolve, and fast.
Precision Medicine in Focus: Ardena’s Strategic Growth & Innovation Under CEO Jeremie Trochu

3 weeks ago | contractpharma.com | Tim Wright

As the biopharma industry advances toward more targeted and complex therapies, the need for specialized CDMO partners has never been greater. Ardena is answering this demand with a precision-medicine-driven approach, supporting the development of innovative molecules through its fully integrated drug substance, drug product, nanomedicine, and bioanalytical services.
Optimizing ATMP Manufacturing

3 weeks ago | contractpharma.com | Tim Wright

Advanced therapy medicinal products (ATMPs) are transforming disease treatment, helping improve patients’ lives worldwide.
Staying Ahead of DSCSA Enforcement in the Pharmaceutical Supply Chain

1 month ago | contractpharma.com | Tim Wright

The Drug Supply Chain Security Act (DSCSA), established in 2013, set a foundation for tracking and verifying pharmaceutical products across the United States. However, while the regulations have been phased in for over a decade, its regulatory requirements continue to evolve, introducing new challenges for the industry.